Drug Trial Radar · NCT00265850
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,334
Actual
Start
Nov 2005
Primary completion
Feb 2015
Study completion Jan 2018
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); SWOG Cancer Research Network; Bristol-Myers Squibb; Aptuit
- First posted
- Dec 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer. RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as fluorouracil, leucovorin, oxaliplatin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibodies together with combination chemotherapy may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with cetuximab and/or bevacizumab in treating patients with colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
bevacizumabBiological
Given IV
cetuximabBiological
Given IV
FOLFOX orDrug
Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
FOLFIRIDrug
Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Up to 5 years post-treatment
Locations
683 sites in 2 countries. Site status is shown where the registry gives one.
Providence Cancer Center at Providence Hospital
Mobile, Alabama
Alaska Regional Hospital Cancer Center
Anchorage, Alaska
Providence Cancer Center
Anchorage, Alaska
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas
NEA Medical Center - Stadium Boulevard
Jonesboro, Arkansas
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
Burbank, California
East Bay Radiation Oncology Center
Castro Valley, California
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California
North Bay Cancer Center
Fairfield, California
Kaiser Permanente - Fremont
Fremont, California
Valley Medical Oncology
Fremont, California
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California
California Cancer Care, Incorporated - Greenbrae
Greenbrae, California
Kaiser Permanente Medical Center - Hayward
Hayward, California
Veterans Affairs Medical Center - Loma Linda (Pettis)
Loma Linda, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California
Camino Medical Group - Treatment Center
Mountain View, California
El Camino Hospital Cancer Center
Mountain View, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Breast Surgeons, Incorporated
Oakland, California
CCOP - Bay Area Tumor Institute
Oakland, California
Larry G Strieff MD Medical Corporation
Oakland, California
Tom K Lee, Incorporated
Oakland, California
Kaiser Permanente Medical Center - Oakland
Oakland, California
St. Joseph Hospital Regional Cancer Center - Orange
Orange, California
Desert Regional Medical Center Comprehensive Cancer Center
Palm Springs, California
Palo Alto Medical Foundation
Palo Alto, California
Valley Medical Oncology Consultants - Pleasanton
Pleasanton, California
Kaiser Permanente Medical Center - Redwood City
Redwood City, California
Kaiser Permanente Medical Center - Richmond
Richmond, California
Kaiser Permanente Medical Center - Roseville
Roseville, California
University of California Davis Cancer Center
Sacramento, California
South Sacramento Kaiser-Permanente Medical Center
Sacramento, California
Kaiser Permanente Medical Center - Sacramento
Sacramento, California
Kaiser Permanente Medical Office -Vandever Medical Office
San Diego, California
Naval Medical Center - San Diego
San Diego, California
San Francisco General Hospital Medical Center
San Francisco, California
Kaiser Permanente Medical Center - San Francisco Geary Campus
San Francisco, California
Showing 40 of 683 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.